0001867096-24-000014.txt : 20240131
0001867096-24-000014.hdr.sgml : 20240131
20240131170432
ACCESSION NUMBER: 0001867096-24-000014
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240131
DATE AS OF CHANGE: 20240131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Edick Paul R
CENTRAL INDEX KEY: 0001531178
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 24583836
MAIL ADDRESS:
STREET 1: C/O NEWLINK GENETICS CORP.
STREET 2: 2503 SOUTH LOOP DR., SUITE 5100
CITY: AMES
STATE: IA
ZIP: 50010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 871082097
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
4
1
wk-form4_1706738662.xml
FORM 4
X0508
4
2024-01-31
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001531178
Edick Paul R
C/O XERIS BIOPHARMA HOLDINGS, INC.
1375 WEST FULTON STREET, SUITE 1300
CHICAGO
IL
60607
1
1
0
0
See Remarks
0
Common Stock
2024-01-31
4
A
0
1500000
0
A
3788064
D
Common Stock
33430
I
By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018
Stock Appreciation Right
2.46
2024-01-31
4
A
0
500000
0
A
2026-03-03
Common Stock
500000
500000
D
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The award will vest in full on the two-year anniversary of the grant date.
Upon exercise, the Stock Appreciation Right will be settled in cash.
Chairman and Chief Executive Officer
/s/ Beth Hecht, as Attorney-in-Fact
2024-01-31